Sidley Represents Sino Biopharm In An Exclusive License Agreement With Astrazeneca.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZeneca
Sidley is representing Sino Biopharmaceutical Limited (Sino Biopharm, HKEX: 1177) in connection with an exclusive license... The post Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZeneca appeared first on Legal Desire Media and Insights.
Sidley Represents Sino Biopharm In An Exclusive License Agreement With Astrazeneca.
Sidley is representing Sino Biopharmaceutical Limited (Sino Biopharm, HKEX: 1177) in connection with an exclusive license agreement entered into between Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Sino Biopharm, and AstraZeneca for the development, manufacturing, and commercialization of the Sino Biopharm’s PDE3/4 inhibitor, TQC3721. Subject to the terms and conditions of the Agreement, AstraZeneca is granted an exc…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
